Philips Research, High Tech Campus, 5656AE Eindhoven, The Netherlands.
Lab Chip. 2013 Sep 21;13(18):3449-70. doi: 10.1039/c3lc50248a.
The concept of "Organs-on-Chips" has recently evolved and has been described as 3D (mini-) organs or tissues consisting of multiple and different cell types interacting with each other under closely controlled conditions, grown in a microfluidic chip, and mimicking the complex structures and cellular interactions in and between different cell types and organs in vivo, enabling the real time monitoring of cellular processes. In combination with the emerging iPSC (induced pluripotent stem cell) field this development offers unprecedented opportunities to develop human in vitro models for healthy and diseased organ tissues, enabling the investigation of fundamental mechanisms in disease development, drug toxicity screening, drug target discovery and drug development, and the replacement of animal testing. Capturing the genetic background of the iPSC donor in the organ or disease model carries the promise to move towards "in vitro clinical trials", reducing costs for drug development and furthering the concept of personalized medicine and companion diagnostics. During the Lorentz workshop (Leiden, September 2012) an international multidisciplinary group of experts discussed the current state of the art, available and emerging technologies, applications and how to proceed in the field. Organ-on-a-chip platform technologies are expected to revolutionize cell biology in general and drug development in particular.
“器官芯片”的概念最近得到了发展,并被描述为由多种不同类型的细胞相互作用组成的 3D(迷你)器官或组织,在微流控芯片中生长,并模拟体内不同细胞类型和器官之间的复杂结构和细胞相互作用,从而能够实时监测细胞过程。结合新兴的 iPSC(诱导多能干细胞)领域,这一发展为开发健康和患病器官组织的体外人类模型提供了前所未有的机会,使我们能够研究疾病发展、药物毒性筛选、药物靶点发现和药物开发的基本机制,并替代动物试验。在器官或疾病模型中捕获 iPSC 供体的遗传背景有望推动“体外临床试验”,降低药物开发成本,并进一步推动个性化医疗和伴随诊断的概念。在洛伦兹研讨会(2012 年 9 月,莱顿)上,一个由国际多学科专家组成的小组讨论了当前的最新技术、可用技术和新兴技术、应用以及如何在该领域取得进展。器官芯片平台技术有望彻底改变细胞生物学,特别是药物开发。